Inve India ▾
SUSUVEN

Suven Life Sciences Q2 FY20 results (Jul–Sep 2019) and concall

Healthcare · Concall AI · Call held 15 Nov 2019

Company page: Suven Life Sciences share price, financials & guidance record

Source transcript

Suven Life Sciences reported strong H1 FY20 performance with significant growth in income, EBITDA, and net profit, driven by robust CRAMS revenue in Q2. The company provided updates on its key NCE pipeline assets, SUVN502 and SUVN3031, with results for the former imminent. Management also detailed CAPEX plans, the demerger timeline, and an optimistic outlook for FY21, while cautioning that Q2's strong numbers included some early sales.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.